Overview


According to FutureWise analysis, the market for Antiretroviral (ARV) Agents is expected to grow with a CAGR of 4.22% over the forecast period 2023-2031. 

Antiretroviral reagents refer to the specialized substances or compounds used in developing, testing, and producing antiretroviral drugs, which are crucial in treating HIV (Human Immunodeficiency Virus) infection. 
These reagents are pivotal in drug discovery, development, and quality control. They are essential for understanding the virus's biology and designing and testing potential drug candidates. In the early stages of drug discovery, antiretroviral reagents are employed to identify and validate potential drug targets within the HIV life cycle. This involves studying various virus components, such as the reverse transcriptase enzyme, protease, integrase, and other vital proteins that facilitate viral replication. Researchers use reagents to investigate the structure and function of these viral components, aiming to identify vulnerabilities that antiretroviral drugs can target. In the production and quality control of antiretroviral drugs, reagents are crucial for ensuring the final product's purity, potency, and consistency. They are used in various analytical techniques, including high-performance liquid chromatography (HPLC), mass spectrometry, and enzyme-linked immunosorbent assays (ELISAs), to quantitatively measure the concentration of active drug components and identify any impurities.

FutureWise Market Research has published a report that provides an insightful analysis of Antiretroviral (ARV) Agents Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antiretroviral (ARV) Agents Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.
  • ViiV Healthcare
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Janssen Pharmaceuticals, Inc.
  • Pfizer
  • Boehringer Ingelheim International GmbH
  • AbbVie Inc.
  • Genentech, Inc.
  • Mylan N.V.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Antiretroviral (ARV) Agents Market:

  • In September of 2022, Merck announced a fresh phase 3 clinical trial to assess the effectiveness of once-daily oral islatravir in treating HIV-1 infection.
  • In August 2022, Gilead obtained worldwide regulatory clearance for Sunlenca (Lenacapavir), a twice-yearly treatment option for HIV.

Ongoing advancements in molecular biology and biotechnology have led to the developing of more sophisticated and precise reagents. These advanced instruments empower scientists to explore the intricate biology of the virus in greater detail, making it easier to uncover fresh drug targets and formulate more potent antiretroviral substances. Moreover, the emergence of drug resistance in HIV strains has necessitated ongoing innovation in antiretroviral reagents. Researchers and pharmaceutical companies are continually working to create reagents that can effectively identify drug-resistant strains, allowing for the optimization of treatment regimens. Additionally, the increasing prevalence of HIV/AIDS in specific regions and populations drives the demand for improved reagents. These tools are crucial for understanding local variations in viral strains, developing targeted therapies tailored to specific patient populations, and driving the market.
However, the virus has a high mutation rate, leading to a wide diversity of strains. This necessitates constant adaptation and refinement of reagents to target the evolving virus, which effectively restraints market growth. Additionally, the high cost of research and development in this field can be a limiting factor, particularly for smaller research institutions or organizations with limited resources, which hampers market growth.

By Drug Type

  • Nucleoside Reverse Transcriptase Inhibitors
  • Multi-Class Combination Products
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Entry Inhibitors — CCR5 Co-Receptor Antagonist
  • Fusion Inhibitors and Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the presence of key market players, technological advancements, and an increased number of HIV cases. Furthermore, drug approvals and product launches are also driving the market's growth; an escalating demand for high-quality healthcare services, technological advancements, and increasing research and development are propelling the market in this region.
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on Antiretroviral (ARV) Agents Market By Drug Type, By Distribution Channel and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections, which are represented in the format of data sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors, which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.  Antiretroviral (ARV) Agents Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antiretroviral (ARV) Agents Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.  Antiretroviral (ARV) Agents Market Analysis Tools

    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Antiretroviral (ARV) Agents Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Nucleoside Reverse Transcriptase Inhibitors
        2. Multi-Class Combination Products
        3. Protease Inhibitors
        4. HIV Integrase Strand Transfer Inhibitors
        5. Non-Nucleoside Reverse Transcriptase Inhibitors
        6. Entry Inhibitors — CCR5 Co-Receptor Antagonist
        7. Fusion Inhibitors and Others

  • 8.  Antiretroviral (ARV) Agents Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
        4. Others

  • 9.   North America Antiretroviral (ARV) Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Antiretroviral (ARV) Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Antiretroviral (ARV) Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Antiretroviral (ARV) Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Antiretroviral (ARV) Agents Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. ViiV Healthcare
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Gilead Sciences, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. GlaxoSmithKline plc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bristol-Myers Squibb Company
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Janssen Pharmaceuticals, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Pfizer
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Boehringer Ingelheim International GmbH
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. AbbVie Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Genentech, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Mylan N.V.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11